TARRYTOWN, N.Y., May 2, 2022
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:
REGN) will webcast management participation as follows:
- BofA Securities Healthcare Conference at 1:20 p.m. PT (4:20 p.m.
ET) on Tuesday, May 10,
2022
- Goldman Sachs 43rd Annual Global Healthcare
Conference at 8:40 a.m. PT (11:40 a.m. ET) on
Tuesday, June 14, 2022
The sessions may be accessed from the "Investors &
Media" page of Regeneron's website at
https://investor.regeneron.com/events-and-presentations.
Replays of the webcasts will be archived on the Company's website
for at least 30 days.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops
and commercializes life-transforming medicines for people with
serious diseases. Founded and led for nearly 35 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to numerous
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, pain, hematologic
conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite®
technologies, such as VelocImmune®, which uses unique
genetically-humanized mice to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For more information, please visit www.Regeneron.com or
follow @Regeneron on Twitter.
Contact Information:
Ryan
Crowe
914.847.8790
ryan.crowe@regeneron.com
View original
content:https://www.prnewswire.com/news-releases/regeneron-announces-investor-conference-presentations-301537436.html
SOURCE Regeneron Pharmaceuticals, Inc.